8-K: Tempest Therapeutics Announces Positive Survival Data for Amezalpat and Provides Second Quarter 2024 Financial Update

Tempest Therapeutics reported positive survival data for amezalpat in liver cancer and provided a financial update for the second quarter of 2024.

Summary

• Tempest Therapeutics announced positive survival data for their drug amezalpat (TPST-1120) in a first-line hepatocellular carcinoma (HCC) study.
• The study showed a six-month improvement in median overall survival (OS) for patients treated with amezalpat in combination with atezolizumab and bevacizumab compared to the control arm.
• The median OS was 21 months for the amezalpat arm versus 15 months for the control arm.
• The hazard ratio (HR) for OS was 0.65, which has been maintained since the previous analysis 10 months earlier when it was 0.59.
• Tempest plans to advance amezalpat into a pivotal Phase 3 trial for first-line HCC, pending FDA feedback.
• They also plan to move TPST-1495 into a Phase 2 study for Familial Adenomatous Polyposis (FAP) in 2024.
• The company ended the second quarter of 2024 with $31.1 million in cash and cash equivalents.
• The net loss for the quarter was $9.6 million, or $0.42 per share, compared to a net loss of $7.6 million, or $0.54 per share, for the same period in 2023.
• Research and development expenses for the quarter were $5.8 million, up from $4.4 million in the same period of 2023.
• General and administrative expenses for the quarter were $3.7 million, compared to $3.1 million for the same period in 2023.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results for amezalpat, which is a significant positive. The financial results are mixed, with increased losses, but the focus is on the clinical progress. The company is moving forward with key programs, which is a positive sign.

Positives

• Amezalpat showed a significant six-month improvement in median overall survival for HCC patients.
• The hazard ratio for amezalpat remained stable at 0.65, indicating consistent efficacy.
• Amezalpat demonstrated a manageable safety profile.
• Preclinical data supports the clinical benefit of amezalpat.
• The company is planning to advance both amezalpat and TPST-1495 into later-stage clinical trials.
• The company has secured funding for the TPST-1495 Phase 2 trial from the National Cancer Institute.

Negatives

• The company experienced a net loss of $9.6 million for the quarter, which is higher than the $7.6 million loss in the same period of 2023.
• Cash reserves decreased from $39.2 million at the end of 2023 to $31.1 million at the end of the second quarter of 2024.
• Research and development expenses increased by $1.4 million compared to the same quarter in 2023.
• General and administrative expenses increased by $0.6 million compared to the same quarter in 2023.

Risks

• The advancement of amezalpat into a Phase 3 trial is subject to obtaining feedback from the FDA.
• The advancement of TPST-1495 into a Phase 2 study is subject to final approval from the NCI.
• The company's cash reserves are decreasing, which may require additional funding in the future.
• Unexpected safety or efficacy data during clinical trials could impact the development of the company's product candidates.
• Changes in the regulatory environment could affect the approval process for the company's drugs.
• The company faces competition from other companies developing cancer therapeutics.

Future Outlook

Tempest Therapeutics plans to advance amezalpat into a registrational Phase 3 study in first-line HCC patients, subject to FDA feedback, and move TPST-1495 into a Phase 2 study for FAP in 2024. They also expect to report data from the combination arm at the two highest TPST-1495 doses in patients with advanced endometrial cancer in 2024.

Management Comments

• Stephen Brady, president and chief executive officer of Tempest, stated that amezalpat demonstrated positive survival benefit as a potential treatment for first-line liver cancer patients.
• He also mentioned that the six-month improvement in survival compared to the standard of care gives them confidence in the potential success of the program.

Industry Context

The positive survival data for amezalpat in HCC is significant in the oncology field, where there is a high unmet need for effective treatments. The company's focus on targeted and immune-mediated therapeutics aligns with current trends in cancer drug development. The advancement of TPST-1495 into a Phase 2 study for FAP also addresses a specific need in cancer prevention.

Comparison to Industry Standards

• The six-month improvement in median overall survival for amezalpat is a notable result compared to standard of care treatments for HCC.
• Other companies developing treatments for HCC include Bayer with Sorafenib and Lenvatinib, and Roche with Atezolizumab and Bevacizumab. The amezalpat results show a potential improvement over these existing treatments.
• The hazard ratio of 0.65 for amezalpat is competitive with other successful oncology drugs in similar trials.
• The planned Phase 3 trial for amezalpat is a standard step in the drug development process, similar to other companies advancing their oncology candidates.

Stakeholder Impact

• Shareholders will likely react positively to the positive clinical trial results for amezalpat.
• Employees may be motivated by the progress of the company's drug development programs.
• Patients with HCC may benefit from the potential approval of amezalpat.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• Tempest plans to advance amezalpat into a registrational Phase 3 study in first-line HCC patients, subject to obtaining feedback from the FDA.
• The company plans to advance TPST-1495 into a Phase 2 study in patients with Familial Adenomatous Polyposis (FAP) in 2024, subject to final approval of NCI.
• They expect to report data from the combination arm at the two highest TPST-1495 doses in patients with advanced endometrial cancer in 2024.

Key Dates

Keywords

Amezalpat, TPST-1120, TPST-1495, Hepatocellular Carcinoma, HCC, Familial Adenomatous Polyposis, FAP, Cancer, Clinical Trial, Phase 3, Phase 2, Survival Data, Biotechnology, Oncology, PPAR antagonist, Prostaglandin receptor antagonist